What do systematic reviews say?

Lithium vs chlorpromazine

The review found no eligible studies for this question.

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Lithium vs chlorpromazine

Lithium showed no clear difference in acceptability: total withdrawals compared with chlorpromazine (low certainty).

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  OR 1.75 [0.92, 3.31]
  2 studies · 262 participants
  Low

Lithium vs chlorpromazine

The review found no eligible studies for this question.

• Lithium for acute mania 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Zuclopenthixol dihydrochloride vs chlorpromazine

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 221 participants
  Low

Zuclopenthixol dihydrochloride vs chlorpromazine

Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  RR 0.54 [0.36, 0.81]
  6 studies · 766 participants
  Low

Zuclopenthixol dihydrochloride vs chlorpromazine

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Zuclopenthixol dihydrochloride vs chlorpromazine

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 64 participants
  Very low

Zuclopenthixol dihydrochloride vs chlorpromazine

It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect (EPSEs) compared with chlorpromazine (very low certainty).

• Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
  RR 0.94 [0.61, 1.45]
  3 studies · 199 participants
  Very low

HALOPERIDOL vs chlorpromazine

It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep Not tranquil or asleep compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  RR 1.93 [1.04, 3.6]
  1 study · 39 participants
  Very low

HALOPERIDOL vs chlorpromazine

It is very uncertain whether HALOPERIDOL changes repeated need for rapid tranquillisation ‐ more that 1 injection compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  RR 1.07 [0.89, 1.28]
  1 study · 30 participants
  Very low

HALOPERIDOL vs chlorpromazine

The review found no eligible studies for this question.

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

HALOPERIDOL vs chlorpromazine

It is very uncertain whether HALOPERIDOL changes global outcome ‐ not any improvement compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  RR 0.15 [0.05, 0.49]
  2 studies · 89 participants
  Very low

HALOPERIDOL vs chlorpromazine

It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ cardiovascular ‐ hypotension compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  RR 0.51 [0.01, 2.6]
  1 study · 30 participants
  Very low

HALOPERIDOL vs chlorpromazine

It is very uncertain whether HALOPERIDOL changes adverse effects: specific ‐ central nervous system ‐ seizures compared with OTHER ANTIPSYCHOTIC: b. CHLORPROMAZINE (very low certainty).

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  RR 0.33 [0.01, 7.58]
  1 study · 30 participants
  Very low

HALOPERIDOL vs chlorpromazine

The review found no eligible studies for this question.

• Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in service utilisation: hospital admission (short term) (low certainty).

• Chlorpromazine versus penfluridol for schizophrenia 2017 · Cochrane Headline outcomes only
  RR 0.19 [0.01, 3.6]
  1 study · 29 participants
  Low

Intervention not reported

• Chlorpromazine versus penfluridol for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Intervention not reported

• Chlorpromazine versus penfluridol for schizophrenia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported